Nonetheless, a comprehensive analysis is imperative to determine the potential cost-effectiveness of employing and integrating 68Ga-PSMA-11 PET/CT for the primary diagnosis of patients with suspected prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.